Reuss JE - Search Results

1

Divergent RET- and BRAF-Mediated Resistance to Osimertinib in EGFR-Mutant NSCLC: A Case Report.

Rehman M, Kim C, Reuss JE, Kiedrowski LA, Garg RJ, Liu SV. Rehman M, et al. Among authors: reuss je. JCO Precis Oncol. 2021 Nov;5:939-942. doi: 10.1200/PO.21.00083. JCO Precis Oncol. 2021. PMID: 34994624 No abstract available.

2

Oral Chemotherapy for Treatment of Lung Cancer.

Jonna S, Reuss JE, Kim C, Liu SV. Jonna S, et al. Among authors: reuss je. Front Oncol. 2020 Apr 28;10:793. doi: 10.3389/fonc.2020.00793. eCollection 2020. Front Oncol. 2020. PMID: 32426292 Free PMC article. Review.

3

Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.

Reuss JE, Gosa L, Liu SV. Reuss JE, et al. Clin Lung Cancer. 2021 Nov;22(6):483-499. doi: 10.1016/j.cllc.2021.07.011. Epub 2021 Jul 25. Clin Lung Cancer. 2021. PMID: 34420859 Review.

4

EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report.

von Buttlar X, Reuss JE, Liu SV, Kim C. von Buttlar X, et al. Among authors: reuss je. JTO Clin Res Rep. 2021 Apr 28;2(6):100179. doi: 10.1016/j.jtocrr.2021.100179. eCollection 2021 Jun. JTO Clin Res Rep. 2021. PMID: 34590027 Free PMC article.

5

Use of on-therapy ctDNA monitoring in a patient with KIF5B-RET fusion positive advanced non-small cell lung cancer: a case report.

Yeung V, Kim C, Kiedrowski LA, Liu SV, Reuss JE. Yeung V, et al. Among authors: reuss je. Transl Lung Cancer Res. 2022 Jan;11(1):111-116. doi: 10.21037/tlcr-21-571. Transl Lung Cancer Res. 2022. PMID: 35242632 Free PMC article.

6

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report.

Wilgucki M, Yeung V, Ho G, Bravo Montenegro GL, Jones G, Reuss JE, Liu SV, Kim C. Wilgucki M, et al. Among authors: reuss je. JTO Clin Res Rep. 2022 Aug 5;3(10):100396. doi: 10.1016/j.jtocrr.2022.100396. eCollection 2022 Oct. JTO Clin Res Rep. 2022. PMID: 36188633 Free PMC article.

7

Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class.

Marks JA, Wilgucki M, Liu SV, Reuss JE. Marks JA, et al. Among authors: reuss je. Curr Oncol Rep. 2022 Dec;24(12):1829-1841. doi: 10.1007/s11912-022-01334-9. Epub 2022 Oct 5. Curr Oncol Rep. 2022. PMID: 36197593 Review.

8

Use of Erdafitinib in FGFR3-Mutated Recurrent Respiratory Papillomatosis.

Yeung V, Sackstein P, Grant NN, Krochmal R, Gandhi N, Aggarwal C, Halmos B, Reuss JE, Liu SV, Kim C. Yeung V, et al. Among authors: reuss je. JCO Precis Oncol. 2022 Nov;6:e2200435. doi: 10.1200/PO.22.00435. JCO Precis Oncol. 2022. PMID: 36455194 No abstract available.

9

Remarkable Intracranial Response to Sotorasib in a Patient With KRAS ^G12C-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report.

Yeh J, Marks JA, Alzeer AH, Sloan EA, Varghese R, Paudel N, Reuss JE, Bergquist PJ, Liu SV, Kim C. Yeh J, et al. Among authors: reuss je. JTO Clin Res Rep. 2022 Nov 6;3(12):100428. doi: 10.1016/j.jtocrr.2022.100428. eCollection 2022 Dec. JTO Clin Res Rep. 2022. PMID: 36471683 Free PMC article.

10

ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.

Schubert L, Elliott A, Le AT, Estrada-Bernal A, Doebele RC, Lou E, Borghaei H, Demeure MJ, Kurzrock R, Reuss JE, Ou SI, Braxton DR, Thomas CA, Darabi S, Korn WM, El-Deiry WS, Liu SV. Schubert L, et al. Among authors: reuss je. Front Oncol. 2023 Apr 24;13:1115405. doi: 10.3389/fonc.2023.1115405. eCollection 2023. Front Oncol. 2023. PMID: 37168365 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page